ArticleEBioMedicine2020
Intranasal Bifidobacterium longum protects against viral-induced lung inflammation and injury in a murine model of lethal influenza infection.
Article in EBioMedicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 68 citations in OpenAlex.
- Probiotic improves respiratory and gastrointestinal health, immune homeostasis, and gut microbiota composition in infants: a randomized controlled trial.Frontiers in nutrition · 2026Trial
- A Three-Arm, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety ofNutrients · 2023Trial
- Gut microbial metabolism of peanuts generates immunoregulatory metabolites.Gut microbes · 2026Article
- Towards optimizing the host response to biotics: a report of an International Scientific Association for Probiotics and Prebiotics working group.Gut microbes · 2026Article
- The gut-lung axis and viral pneumonia: Unrevealing the gut microbiota.Pharmaceutical science advances · 2026Review
- Associations of forest vs. urban environmental exposure with well-being and nasal microbiome composition: An exploratory pilot study.Environmental research · 2026Article
- B. adolescentis alleviates inflammation and suppresses PGE2 through remodling gut microbiota to attenuate pulmonary fibrosis in aging mice.NPJ science of food · 2025Article
- The gut microbiota limits systemic inflammation during neurotrophic viral CNS infection by priming tonic type I interferon signaling.Journal of neuroinflammation · 2025Article
- Pathogenic bacteria enriched in the oral microbiota might be associated with recurrent pulmonary infections in elderly individuals.Aging clinical and experimental research · 2025Article
- Article
- Gut microbiota characteristics in neonatal respiratory distress syndrome and the therapeutic potential of probiotics in recovery.Frontiers in microbiology · 2025Article
- Engineered probiotic Escherichia coli elicits immediate and long-term protection against influenza A virus in mice.Nature communications · 2024Article
- Genetically Predicted Peripheral Immune Cells Mediate the Effect of Gut Microbiota on Influenza Susceptibility.International journal of molecular sciences · 2024Article
- Host tracheal and intestinal microbiomes inhibitMicrobiology spectrum · 2024Article
- Article
- A genome-wide association study reveals the relationship between human genetic variation and the nasal microbiome.Communications biology · 2024Article
- Article
- Ruhao Dashi granules exert therapeutic effects on H1N1 influenza virus infection by altering intestinal microflora composition.Frontiers in microbiology · 2024Article
- The Respiratory Microbiome in Paediatric Chronic Wet Cough: What Is Known and Future Directions.Journal of clinical medicine · 2023Review
- Lactobacillus rhamnosus Restores Antiviral Signaling and Attenuates Cytokines Secretion from Human Bronchial Epithelial Cells Exposed to Cigarette Smoke and Infected with SARS-CoV-2.Probiotics and antimicrobial proteins · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 5 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundProphylactic strategies are urgently needed for prevention of severe inflammatory responses to respiratory viral infections. Bacterial-host interactions may modify the immune response to viral infections.
methodsWe examined the contribution of Intranasal administration of two different Bifidobacterium longum strains or its isolated cell wall in controlling viral induced inflammation using a murine model of influenza infection. We monitored mortality and morbidity over a 10-day period and viral load, differential broncho alveolar lavage (BAL) fluid inflammatory cell counts, Lung tissue histology, BAL and serum cytokines, markers of vascular damage and cell death were quantified.
findingsIntranasal administration of Bifidobacterium longum35624® or its isolated cell wall prior to virus inoculation significantly reduced viral load within the lungs and significantly improved survival. Reduced viral load was associated with reduced lung injury as suggested by cell death and vascular leakage markers, a shift from neutrophil to macrophage recruitment, reduced inflammatory cytokine levels (including IL-6), reduced type 1 and 2 interferon levels, but increased levels of interferon-λ and surfactant protein D. These protective effects were maintained when the bifidobacterial cell wall preparation was administered 24 h after viral inoculation. The protective effects were also observed for the Bifidobacterium longumPB-VIR™ strain.
interpretationExposure to these bifidobacterial strains protect against the inflammatory sequelae and damage associated with uncontrolled viral replication within the lung.
fundingThis work has been funded, in part, by a research grant from GlaxoSmithKline, PrecisionBiotics Group Ltd., Swiss National Science Foundation grants (project numbers CRSII3_154488, 310030_144219, 310030_127356 and 310030_144219) and Christine Kühne - Center for Allergy Research and Education (CK-CARE).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.